French company Neovacs and Spanish-based 3P Biopharmaceuticals have collaborated to manufacture interferon alpha (IFNα).
The partnership follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from Amegabiotech.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Neovacs CEO Miguel Sieler said: “This partnership is in line with the recent license agreement signed with Amegabiotech.
"The completion of these two steps allows us to secure the complete production chain for the manufacture of IFNα, one of the primary raw materials of our most advanced product, IFNα Kinoid.
“In addition, the agreement complements the partnership signed earlier this year with Stellar Biotechnologies, the supplier of the other main component of our vaccine IFNα Kinoid, Keyhole Limpet Hemocyanin (KLH).”
Within the framework of the partnership, Stellar holds 30% of Neovacs’ production subsidiary Neostell.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith the licence agreement in place, Neovacs will be able to directly transfer Amegabiotech's technology to 3P Biopharmaceuticals’ production site, where the IFNα cytokine will be manufactured.
3P Biopharmaceuticals business development director Elena Erroba said: “3P Biopharmaceuticals is very happy with this collaboration.
“It will allow 3P Biopharmaceuticals to contribute to a very innovative therapeutic approach, with our strong competence in the field of manufacturing high-quality protein.”
3P Biopharmaceuticals is specialised in the process development and GMP manufacturing of biologics and cell therapy products in mammalian, microbial and yeast expression systems.
